Innocoll AG (INNL) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Innocoll AG (NASDAQ:INNL) from a buy rating to a hold rating in a research note published on Tuesday morning.

According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “

Separately, FBR & Co initiated coverage on shares of Innocoll AG in a report on Thursday, June 30th. They issued an outperform rating and a $18.00 price objective on the stock.

Innocoll AG (NASDAQ:INNL) opened at 6.03 on Tuesday. The stock’s market cap is $146.85 million. Innocoll AG has a one year low of $4.57 and a one year high of $13.72. The firm’s 50 day moving average price is $6.03 and its 200 day moving average price is $6.84.

Innocoll AG (NASDAQ:INNL) last posted its earnings results on Wednesday, August 17th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.11. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.04 million. Innocoll AG had a negative net margin of 1,139.95% and a negative return on equity of 1,226.28%. Equities analysts forecast that Innocoll AG will post ($2.41) earnings per share for the current year.

About Innocoll AG

Innocoll Holdings plc is a commercial-stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. The Company utilizes its collagen-based technology platform to develop biodegradable and fully bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.

5 Day Chart for NASDAQ:INNL

Get a free copy of the Zacks research report on Innocoll AG (INNL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Innocoll AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll AG and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.